In HCC, response rates of 15–20% (compared to 2–3% on first-line Sorafenib [13,14]) to Nivolumab (anti-PD-1) were reported from a phase I/II trial (CheckMate 040) [15,16]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.